Expression and Significances of Contactin-1 in Human Gastric Cancer

Table 3

Correlation of clinicopathologic parameters with VEGF-C, VEGFR-3, and CNTN-1 expression in gastric cancer (𝑛/%).

Clinicopathological features	Total cases	VEGF-C			VEGFR-3			CNTN-1
		(+)	(−)	P	(+)	(−)	P	(+)	(−)	P
Age (ys)				0.925						0.972
≧60	69/65.7	39/66.1	30/65.2		47/69.1	22/59.5		40/65.6	29/65.9
<60	36/34.3	20/33.9	16/34.8		21/30.9	16/40.5		21/34.4	15/34.1
Gender				0.676			0.571			0.545
Male	73/69.5	42/71.2	31/67.4		46/67.6	27/73.0		41/67.2	32/72.7
Female	32/30.5	17/28.8	15/32.6		22/32.4	10/27.0		20/34.8	12/27.3
Tumor size				0.177			0.317			0.035
≧5 cm	58/55.2	36/61.0	22/47.8		40/58.8	18/48.6		39/63.9	19/43.2
<5 cm	47/44.8	23/39.0	24/52.2		28/41.2	19/51.4		22/36.1	25/56.8
Tumor location				0.218			0.320			0.098
Upper	17/16.2	11/18.6	6/13.0		13/19.1	4/10.8		6/9.8	11/25.0
Middle	34/32.4	15/25.5	19/41.3		19/27.9	15/40.5		20/32.8	14/31.8
Lower	54/51.4	33/55.9	21/45.7		36/52.9	18/58.7		35/57.4	19/43.2
Lauren’s classification				0.071			0.885			0.328
Intestinal	70/66.7	35/59.3	35/76.1		45/66.2	25/67.6		43/70.5	27/61.4
Diffuse	35/33.3	24/40.7	11/23.9		23/33.8	12/32.4		18/29.5	17/38.6
TNM stage				0.001			<0.001			0.002
I + II	41/39.0	15/25.4	26/56.5		18/26.5	23/62.2		16/26.2	25/56.8
III + IV	64/61.0	44/74.6	20/43.5		50/73.5	14/37.8		45/73.8	19/43.2
Vascular invasion				0.526			0.179			0.385
(+)	26/24.8	16/32.2	10/15.2		14/20.6	12/32.4		17/27.9	9/20.5
(−)	79/75.2	43/67.8	36/84.8		54/79.4	25/67.6		44/72.1	35/79.5
Serosa invasion				0.363			0.084			0.148
(+)	37/35.2	23/39.0	14/30.4		28/41.2	9/24.3		18/29.5	19/43.2
(−)	68/64.8	36/61.0	32/69.6		40/58.8	28/75.7		43/70.5	25/56.8
Lymphatic invasion				<0.001			<0.001			0.001
(+)	66/62.9	49/83.1	17/37.0		54/79.4	12/32.4		47/77.0	19/43.2
(−)	39/37.1	10/16.9	29/63.0		14/20.6	25/67.6		14/23.0	25/56.8
Lymph node metastasis				<0.001			<0.001			<0.001
(+)	70/66.7	49/83.1	21/45.7		54/79.4	16/43.2		50/82.0	20/45.5
(−)	35/33.3	10/16.9	25/54.3		14/20.6	21/56.8		11/18.0	24/54.5